Virion glycosylation influences mycobacteriophage immune recognition.
bacteriophages
phage therapy
viral glycosylation
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
12 07 2023
12 07 2023
Historique:
received:
06
04
2023
revised:
19
05
2023
accepted:
25
05
2023
pmc-release:
12
07
2024
medline:
17
7
2023
pubmed:
18
6
2023
entrez:
17
6
2023
Statut:
ppublish
Résumé
Glycosylation of eukaryotic virus particles is common and influences their uptake, trafficking, and immune recognition. In contrast, glycosylation of bacteriophage particles has not been reported; phage virions typically do not enter the cytoplasm upon infection, and they do not generally inhabit eukaryotic systems. We show here that several genomically distinct phages of Mycobacteria are modified with glycans attached to the C terminus of capsid and tail tube protein subunits. These O-linked glycans influence antibody production and recognition, shielding viral particles from antibody binding and reducing production of neutralizing antibodies. Glycosylation is mediated by phage-encoded glycosyltransferases, and genomic analysis suggests that they are relatively common among mycobacteriophages. Putative glycosyltransferases are also encoded by some Gordonia and Streptomyces phages, but there is little evidence of glycosylation among the broader phage population. The immune response to glycosylated phage virions in mice suggests that glycosylation may be an advantageous property for phage therapy of Mycobacterium infections.
Identifiants
pubmed: 37329881
pii: S1931-3128(23)00221-4
doi: 10.1016/j.chom.2023.05.028
pmc: PMC10527164
mid: NIHMS1910425
pii:
doi:
Substances chimiques
Glycosyltransferases
EC 2.4.-
Polysaccharides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1216-1231.e6Subventions
Organisme : NIGMS NIH HHS
ID : U24 GM129547
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM131729
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI085062
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI089443
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008208
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests G.F.H. received support from Janssen Inc. through a Collaborative Research Agreement, which did not fund work in this report. J.V.W. serves on the Scientific Advisory Board of Quidel and an Independent Data Monitoring Committee for GlaxoSmithKline, neither involved in the present work.
Références
mBio. 2021 May 20;12(3):
pubmed: 34016711
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Clin Infect Dis. 2023 Jan 6;76(1):103-112
pubmed: 35676823
Immunome Res. 2009 Sep 24;5:4
pubmed: 19778434
Virol J. 2020 Aug 17;17(1):124
pubmed: 32807206
Front Immunol. 2021 Jan 22;11:573928
pubmed: 33552045
G3 (Bethesda). 2022 Aug 25;12(9):
pubmed: 35894699
Nat Microbiol. 2017 Feb 06;2:16274
pubmed: 28165460
Nat Commun. 2022 May 3;13(1):2313
pubmed: 35504908
Curr Opin HIV AIDS. 2020 Sep;15(5):267-274
pubmed: 32675574
Pulm Ther. 2023 Mar;9(1):91-107
pubmed: 36583829
Environ Microbiol. 2021 Aug;23(8):4576-4594
pubmed: 34190387
Cell. 2003 Apr 18;113(2):171-82
pubmed: 12705866
Front Mol Biosci. 2021 Apr 13;8:629873
pubmed: 33928117
Cell. 1998 Jul 10;94(1):55-60
pubmed: 9674427
Microorganisms. 2021 Nov 23;9(12):
pubmed: 34946016
J Mol Biol. 2010 Mar 19;397(1):119-43
pubmed: 20064525
mBio. 2021 Mar 30;12(2):
pubmed: 33785627
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10771-6
pubmed: 23690590
Microbiology (Reading). 2009 Sep;155(Pt 9):2962-2977
pubmed: 19556295
Elife. 2015 Apr 28;4:e06416
pubmed: 25919952
Viruses. 2021 Nov 01;13(11):
pubmed: 34835003
Microbiology (Reading). 2021 Apr;167(4):
pubmed: 33826491
BMC Bioinformatics. 2011 Oct 12;12:395
pubmed: 21991981
Virology. 2012 Dec 20;434(2):187-201
pubmed: 23084079
Viruses. 2020 Mar 08;12(3):
pubmed: 32182721
mBio. 2021 Mar 30;12(2):
pubmed: 33785625
Front Cell Infect Microbiol. 2018 Jan 09;7:529
pubmed: 29376033
PLoS One. 2015 Mar 05;10(3):e0118725
pubmed: 25742016
Nat Med. 2021 Aug;27(8):1357-1361
pubmed: 34239133
Annu Rev Biochem. 2008;77:521-55
pubmed: 18518825
Cell. 2022 May 26;185(11):1860-1874.e12
pubmed: 35568033
Structure. 2023 Mar 2;31(3):282-294.e5
pubmed: 36649709
PLoS Pathog. 2022 Jul 7;18(7):e1010602
pubmed: 35797343
Trends Microbiol. 2007 May;15(5):211-8
pubmed: 17398101
Annu Rev Virol. 2020 Sep 29;7(1):37-61
pubmed: 32991269
Nucleic Acids Res. 2022 Jul 22;50(13):e75
pubmed: 35451479
Cell. 2023 Jan 5;186(1):17-31
pubmed: 36608652
Mol Microbiol. 1990 Nov;4(11):1911-9
pubmed: 2082148
Cell Rep. 2021 May 25;35(8):109179
pubmed: 34004174
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Annu Rev Med. 2022 Jan 27;73:197-211
pubmed: 34428079
Infect Immun. 2021 Jul 15;89(8):e0081220
pubmed: 34097459
Nat Med. 2019 May;25(5):730-733
pubmed: 31068712
Microbiol Spectr. 2018 Oct;6(5):
pubmed: 30291704
Protein Sci. 2018 Jan;27(1):14-25
pubmed: 28710774
PLoS One. 2012;7(5):e38028
pubmed: 22675428
Virulence. 2022 Dec;13(1):670-683
pubmed: 35436420
G3 (Bethesda). 2022 Nov 4;12(11):
pubmed: 36161315